financetom
Business
financetom
/
Business
/
VersaBank Says Public Offering Underwriters Fully Exercised Overallotment Option
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
VersaBank Says Public Offering Underwriters Fully Exercised Overallotment Option
Dec 24, 2024 10:13 AM

12:37 PM EST, 12/24/2024 (MT Newswires) -- VersaBank ( VBNK ) said underwriters of its public offering fully exercised an option to purchase 849,056 additional common shares at $13.25 apiece, adding almost $11.3 million in gross proceeds.

That brought the total offering to around 6.51 million shares with gross proceeds of $86.25 million, VersaBank ( VBNK ) said Tuesday in a statement.

The funds will be used to support general banking purposes, VersaBank ( VBNK ) said.

VersaBank ( VBNK ) shares fell 0.8% in recent Tuesday trading.

Price: 13.42, Change: -0.11, Percent Change: -0.81

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eos Energy Receives $315.5 Million Investment From Cerberus
Eos Energy Receives $315.5 Million Investment From Cerberus
Jun 24, 2024
09:15 AM EDT, 06/24/2024 (MT Newswires) -- Eos Energy Enterprises ( EOSE ) said Monday that an affiliate of Cerberus Capital has invested up to $315.5 million to enable Eos Energy ( EOSE ) to restructure existing debt and expand operations. The investment is structured as a $210.5 million delayed draw term loan contingent on operational milestones through April 2025...
Altimmune Stock Is Rising Monday: What's Driving The Action?
Altimmune Stock Is Rising Monday: What's Driving The Action?
Jun 24, 2024
Altimmune Inc ( ALT ) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide. What Happened: Altimmune ( ALT ) said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes Association’s...
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'
Evolus Completes FDA Premarket Approval Submission for Evolysse Dermal Fillers for 'Smile Lines'
Jun 24, 2024
09:03 AM EDT, 06/24/2024 (MT Newswires) -- Evolus ( EOLS ) said Monday it submitted the final part of its premarket approval application to the US Food and Drug Administration for its Evolysse dermal filler products for nasolabial folds, also known as smile lines. The application covers Evolysse Lift and its softer alternative Evolysse Smooth, Evolus ( EOLS ) said,...
Natural Gas Eases Early as the Heat Dome Cools
Natural Gas Eases Early as the Heat Dome Cools
Jun 24, 2024
09:16 AM EDT, 06/24/2024 (MT Newswires) -- Natural gas prices eased early on Monday as a heat dome that pushed temperatures in the Upper Midwest and Northeast to record highs last week and raised air-conditioning demand abated. Gas for July delivery was last seen down US$0.02 to US$2.69 per million British thermal units. The drop comes as temperatures in northern...
Copyright 2023-2025 - www.financetom.com All Rights Reserved